Thread by @TumorBoardTues

#TumorBoardTuesday #ASCO2022

📢@ASCO is only a few days away & we really wanted to put out our top abstracts to👀for

🙏note - we viewed several thousand titles - so we definitely may have missed some‼️
👉And these are not in any particular order

✅But enjoy, RT, and reply😀

#TumorBoardTuesday #ASCO2022
"Emerging"🎯💊
✅Dr. Jones👨‍🏫the Ph2 FAKTION trial of fulv/capi vs fulv/placebo for Breast Ca
➡️Capi⬆️mOS by 6 mos
➡️This⬆️jumped to 19 ms if the tumor harbored PIK3CA or AKT1 activating OR PTEN inactivating🧬mutations
🔎Breast Ca Oral Abstract # 1005

#TumorBoardTuesday #ASCO2022
"Emerging"🎯💊
✅Dr. Rixe👨‍🏫PhI data4⃣OBT076, an ADC🎯the CD205/Ly75 Ag - a receptor⬆️on immunosuppressive dendritic cells
➡️1⃣PR & 6⃣SD out of 2⃣0⃣pts
➡️Near CR in 2⃣pts who then had pembro
🤔Why wasn't☝️more than a poster❓
🔎Abs 3028, Poster 20

#TumorBoardTuesday #ASCO2022
"Emerging"🎯💊
✅@hoperugo & @stolaney1 present a randomized Ph3 trial of the Trop-2 directed ADC, sacituzumab govitecan vs physician’s choice for Breast Ca
➡️No data was in the abstract – but stay tuned‼️
🔎Breast Cancer Oral Abstract # LBA1001

#TumorBoardTuesday #ASCO2022
"Emerging"🎯💊
✅I don’t know if this agent will have any impact – but I think it has a cool name😄
➡️“A selective oral embryonic ectoderm development (EED) inhibitor”
Vincent Ribrag
🔎Abstract # 3083, Poster # 75

#TumorBoardTuesday #ASCO2022
HER3🎯💊
👇HER3 is a legitimate target in Breast Ca
✅Ian E. Krop👨‍🏫the results of a Ph1/2 trial of Patritumab deruxtecan, a HER3-directed ADC in pts with HER3 exp Breast Ca
➡️Out of 113 patients, the ORR was 30%
🔎Breast Cancer Oral Abst 1002

#TumorBoardTuesday #ASCO2022
HER3🎯💊
👇HER3 is a🎯in Lung Ca2⃣
✅Dr. Steur👨‍🏫Ph1 trial of Patritumab deruxtecan in NSCLC
😮BUT the predictor was NOT⬆️HER3
➡️It was a driver🧬alteration
👉e.g. K/NRAS/EGFR/ROS/ALK
➡️ORR in the driver group = 35%
🔎NSCLC Poster🗣️Abs 9017, Poster 5

#TumorBoardTuesday #ASCO2022
DDR🎯💊
🎯DDR🧬mutated Ca with other DDRinh is a🔥topic
✅Dr. Lynch & TimYap👨‍🏫a PhI/2 trial of CYT-0851, an inhibitor of RAD51-HR
✅4⃣6⃣evaluable pts
➡️1 CR & 1 PR in 12 lymphoma pts
➡️1 PR & 16 SD in 34 solid tumor pts
🔎Abst 3084, Poster 76

#TumorBoardTuesday #ASCO2022
DDR🎯💊
PARPi to🎯other DDR🧬mutations is also a🔥topic
✅@TGeorgeMD👨‍🏫a Ph2 trial of niraparib in tumors w/BAP1 or other DDR alterations
➡️Niraparib➡️response in 78% of BAP1-mutated tumors
➡️But 0% in other DDR mutated Ca
🔎Abst 3122, Poster 114

#TumorBoardTuesday #ASCO22
Resistance to🎯💊
✅Dr. Harada from @MSKCancerCenter 👨‍🏫pts w/NTRK-fusion➕tumors progressed on laro/entrectinib
➡️POST-PROGRESSION🧬NGS
➡️On🎯solvent-front or gatekeeper resist=83%
➡️Off🎯resist=11%
➡️Lots more details
🔎Abst 3104, Poster 96

#TumorBoardTuesday #ASCO22
Resistance to🎯💊
(2 part)
✅Dr. Darabi examined 118,000 solid tumor sequences for the presence of BRCA1/2 reversion mutations
➡️Only 54 were identified
🔎Abst 3132, Poster 124

#TumorBoardTuesday #ASCO22
Resistance to🎯💊
✅Also Dr. Decker & @KReissMD🔬31124 tissue & 3870🌊HBP Ca pt samples
➡️Only 63 reversions
🔎Abst 4156, Poster 141

🤔BUT, how many were platinum/PARP resistant❓

👉We still don’t really know how often🖕mutations cause resistance

#TumorBoardTuesday #ASCO22
RET🎯💊
✅@VivekSubbiah provides an update on selpercatinib in pts w/ RET fusion➕Ca
➡️Out of 45 pts w/RET-fusion➕Ca
👉2 had a complete response
👉16 had a partial response
👉The median duration of response was 25 months‼️
🔎Abst 3094, Poster 86

#TumorBoardTuesday #ASCO22
MDM2🎯💊
🔥MDM2i are showing real promise
✅Dr. McKean🧑‍🏫a Ph2 trial of the MDM2i alrizomadlin (APG-115)➕pembro
➡️ORR=24%
➡️40% in MPNST
🔎Mel Poster🗣️Session, Abst 9517, Poster 110

✅Dr. Dumbrava🧑‍🏫a TPS Ph2 trial milademetan➕pemrbo
🔎Abst TPS3165

#TumorBoardTuesday #ASCO22
Wee1 and Cyclin E1🎯💊
✅Dr. Au-Yeung🧑‍🏫a Ph2 trial of the Wee1i, adavosertib in HG serous Ov Ca with⬆️Cyclin E1
➡️Cyclin E1🔬by IHC
➡️53% ORR‼️
🔎Gyn-Onc Poster🗣️Session, Abst 5515, Poster 394

#TumorBoardTuesday #ASCO22
Wee1 and Cyclin E1🎯💊
✅Dr. Alaa Embaby will present the Cyclin E analysis for his groups carbo + adavosertib trial in ovarian cancer
🔎Abst 5516, Poster 395

✅And there are novel Wee1i coming
🔎Abst TPS2702

#TumorBoardTuesday #ASCO22
🔥Tumor🔬
✅Dr. McDonnell & @HHampel1🔬5044 Ca pts4⃣germ path🧬mut in a Fanconi Anemia gene
🤯20% of pts harbor a path Ca gene❓‼️
➡️11% w/a path mut in a FA gene
🔎Poster🗣️Session Abst 10521, Poster 399

📢So yes – GERMLINE🧬TESTING4⃣ALL CA PATIENTS

#TumorBoardTuesday #ASCO22
🔥Tumor🔬
📢ALSO🧬muts labelled as VUSs become clearer over⌛️with⬆️data input
✅Dr. Makhoon🧑‍🏫that VUSs CAN be reclassified as “actionable”➡️new🎯💊options
➡️Testing btw 2013 & 2019
➡️2715 pts, 13% of VUSs changed to actionable
🔎Abst 10512, Poster 391

#TumorBoardTuesday #ASCO22
cMET🎯💊
✅May not be news to Lung Ca😷, but news to me!
✅Dr. Camidge🧑‍🏫a Ph2 trial of Teliso-V, a cMET-🎯 ADC (LUMINOSITY)
➡️ORR amongst 136 cMET overexpressed NSCLC tumor patients=37%
🔎Lung Ca Poster🗣️Session Abst 9016, Poster 4

#TumorBoardTuesday #ASCO22
KRASG12C🎯💊
🔥Important updates on🎯KRASG12C-mutated cancers
✅Dr. Spira🧑‍🏫a Ph1/2 trial of adagrasib in KRASG12C-mutated NSCLC
➡️ORR in 116 patients=43%
🔎Lung Ca Oral Session Abst 9002

🤔Conclusion – PLEASE check for this mutation in your patients

#TumorBoardTuesday #ASCO22
Claudin🎯💊
🔥Claudin 18.2 has become a “hot”🎯
✅Dr. Huang 🧑‍🏫13 pts Tx w/MIL93, an anti-Claudin18.2 mAb
➡️1⃣pt w/ a PR, 3 w/ SD
🔎Abst 3086, Poster 78

✅Dr. Gong🧑‍🏫Ph1 trial of Q-1802, a Claudin18.2/PD-L1 bsAB
➡️ORR 1⃣/9⃣pts
🔎Abst 2568, Poster 223

#TumorBoardTuesday #ASCO22
Folate Receptor🎯💊
🔥Have to admit - didn’t realize how many Folate receptor-alpha (FRa)🎯💊 are in development
✅Dr. Hayato🧑‍🏫a Ph1 trial of MORAb-202, an ADC targeting FRα
➡️Only PK data was in the abstract
🔎Abst 3090, Poster 82

#TumorBoardTuesday #ASCO22
Folate Receptor🎯💊
🔥Two other trials in progress will be presented too
✅Wen Wee Ma from @MayoCancerCare🧑‍🏫a trial of ELU-FRα-1
🔎Abst TPS3158, Poster 146b
And
✅Kaiwen Li🧑‍🏫a trial of bi-ligand-drug conjugate CBP-1018
🔎Abst TPS2694, Poster 334b

#TumorBoardTuesday #ASCO22
STING Agonist💊
🔥OK – this is not really “biomarker-directed therapy”, but this is a very cool pathway that is being explored for cancer therapy
✅Dr. Diamond 🧑‍🏫the TPS of a novel STING agonist ADC, TAK-500 +/- pembro
🔎Abst TPS2690, Poster 333a

#TumorBoardTuesday #ASCO22
😟Beware the Failed Biomarker Predictors

🙏These tweets carry no criticism for the authors – to the contrary, congratulations on well designed trials, AND on the courage to present negative results
BUT – not all drug-biomarker combos are beneficial:

#TumorBoardTuesday #ASCO22
😟Beware the Failed Biomarker Predictors

✅Tazemetostat was not helpful in peds tumors w/ EZH2 mutations or loss of SMARCB1 or SMARCA4
🔎Abst 10009, Poster 224

✅Olaparib was not beneficial in IDH1 and IDH2-mutated gliomas
🔎Abst 2035, Poster 373

#TumorBoardTuesday #ASCO22
😟Beware the Failed Biomarker Predictors

✅And temsirolimus was not helpful for mTOR-mutated cancers
🔎Abst 3114, Poster 106

📢Conclusion – please don’t use these agents off label, just because the molecular report suggests you can

#TumorBoardTuesday #ASCO22
HER2🎯💊
🔥Following the👍results of chemo+pembro+tras4⃣HER2+ UGI Ca...
✅Dr. Sheng 🧑‍🏫a novel HER2 ADC
✅The “drug” payload is an anti-PD-1 IgG4
➡️41 bladder Ca pts
➡️ORR=83%
➡️ORR=50% even in HER2 Lo/Neg pts
🔎GU Poster🗣️Session Abst 4518, Poster 10

#TumorBoardTuesday #ASCO22
HER2🎯💊
✅@KReissMD🧑‍🏫an exciting new agent, CT-0508
✅This is a first in class CAR-M, comprised of autologous monocyte derived macrophages expressing an anti-HER2 CAR
➡️ The abstract results were very early
🔎Abst 2533, Poster 189

#TumorBoardTuesday #ASCO22
HER2🎯💊
🔥Finally, we are all waiting to see the plenary session by Dr. Shanu Modi
✅The Phase 3 DESTINY-Breast04 trial of T-DXd vs physician’s choice in pts with HER2-low advanced breast cancer
🔎Plenary Session, Abstract # LBA3

😃See you all there

#TumorBoardTuesday #ASCO22

Wait!!! Missed a very important biomarker based trial

#TumorBoardTuesday #ASCO22
🎯💊 for PNET
🔥MGMT🔬is🔑

✅@PamelaKunzMD🧑‍🏫a Rand trial of Tem vs CAPE/TEM for PNETs
➡️133 efficacy eval pts enrolled
➡️mPFS & mOS for Cape/Tem was > Tem
🤯Odds Ratio for response was 6.38 to 9.79 for MGMT low OR methylated
🔎GI Ca Oral Abst 4004